Manager TitleAgeSince
Director of Finance/CFO 71 2021-11-30
Chief Tech/Sci/R&D Officer 60 -
Chief Operating Officer - 2001-12-31
Director TitleAgeSince
Director/Board Member 69 2010-08-31
Director/Board Member 74 2011-05-17
Chairman 70 2010-09-22
Change 5-day change 1-year change 3-year change Capi.($)
-.--%+0.56% - - 1.62B
+1.86%+0.48%+55.50%+163.08% 1,082B
+3.57%+3.29%+68.60%+61.03% 633B
+3.99%+3.05%+37.93%+93.37% 461B
+3.86%+1.64%+31.35%+24.29% 338B
-0.56%+0.96%+39.86%+36.64% 299B
-0.08%+1.30%+30.37%+44.02% 291B
-1.54%+2.81%-27.56%-39.45% 222B
+3.55%+4.41%+25.45%+66.28% 202B
+4.21%+2.65%+17.47%+71.11% 163B
Average +1.89%+4.58%+31.00%+57.82% 410.27B
Weighted average by Cap. +2.24%+5.53%+41.78%+83.01%
Logo Taro Pharmaceutical Industries Ltd.
Taro Pharmaceutical Industries Ltd. (Taro) is a science-based pharmaceutical company. The Company operates principally through three entities: Taro Pharmaceutical Industries Ltd. (Taro Israel), and two of its subsidiaries, Taro Pharmaceuticals Inc. (Taro Canada) and Taro U.S.A. The Company markets over 200 pharmaceutical products in over 25 countries. The Company's owned product brands include Rokacet, with generic names, such as acetaminophen, codeine and caffeine; Topicort, with the generic name, desoximetasone; Etopan, with the generic name etodolac, and Ovide, with the generic name, malathion, among others. The Company's other generic products include acetazolamide, adapalene, alclometasone dipropionate, amiodarone hydrochloride, ammonium lactate, augmented betamethasone dipropionate, cetirizine hydrochloride, clobetasol propionate, clomipramine hydrochloride, clorazepate dipotassium, fluorouracil, ketoconazole, metronidazole, mupirocin and warfarin sodium, among others.
Employees
1,554
  1. Stock Market
  2. Stocks
  3. TARO Stock